Compare MRCY & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 1997 | 2020 |
| Metric | MRCY | LEGN |
|---|---|---|
| Price | $97.93 | $29.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $80.00 | $61.33 |
| AVG Volume (30 Days) | 503.6K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $912,020,000.00 | N/A |
| Revenue This Year | $6.59 | $42.68 |
| Revenue Next Year | $9.56 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.19 | N/A |
| 52 Week Low | $47.53 | $16.24 |
| 52 Week High | $103.81 | $45.30 |
| Indicator | MRCY | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.71 | 65.66 |
| Support Level | $73.27 | $25.01 |
| Resistance Level | $103.81 | $29.69 |
| Average True Range (ATR) | 4.57 | 2.17 |
| MACD | 0.79 | -0.12 |
| Stochastic Oscillator | 97.15 | 82.32 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.